3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Cognitive Dysfunction
1
Chemotherapy-Related Cognitive Impairment
1
Interventions
Cisplatin
270
Oxaliplatin
195
Carboplatin
191
Capecitabine
184
Docetaxel
178
apatinib
164
Paclitaxel
163
Bevacizumab
159
Gemcitabine
156
Radiotherapy
147
camrelizumab
146
Fluorouracil
144
Cyclophosphamide
126
Irinotecan
120
Drug Therapy
120
sintilimab
108
Etoposide
99
anlotinib
90
S 1 (combination)
89
pembrolizumab
86
Leucovorin
86
toripalimab
78
Pemetrexed
78
Doxorubicin
77
tislelizumab
76
Dexamethasone
71
Trastuzumab
65
Neoadjuvant Therapy
65
Rituximab
62
Cetuximab
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Unknown
×
Ashwagandha
×
Clear all
NCT04092647
2023-06-15
Ashwagandha for Cognitive Dysfunction
Sutter Health
Phase 2
Unknown
80 enrolled